Home›Research›Compare›ARA-290 vs NAD+
Peptide ComparisonARA-290 vs NAD+
Both are Longevity & Cellular peptides.
ARA-290
Cibinetide
Half-life: ~2 min (IV); ~10–20 min (SC)
17 providers listed
NAD+
NAD
Half-life: ~1–2 hours (IV); variable (oral)
451 providers listed
NAD+ has a longer half-life than ARA-290, so it generally needs less frequent dosing.
ARA-290
Half-life
~2 min (IV); ~10–20 min (SC)
NAD+
Half-life
~1–2 hours (IV); variable (oral)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | NAD+ |
| Further along in FDA review | ARA-290 |
| Less frequent dosing (longer half-life) | NAD+ |
| Oral administration option | NAD+ |
| Lower typical price per mg | NAD+ |
| More provider options (17 vs 451) | NAD+ |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
ARA-290
NAD+
ARA-290
NAD+
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and…
Mitochondrial quality control in human ageing and longevity.
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
About NAD+
NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
ARA-290
No established clinical contraindications
NAD+
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
ARA-290
NAD+
Where to source these peptides
ARA-290
17 listed
Browse directory →
Providers offeringNAD+
451 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). ARA-290 vs NAD+ — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/ara-290/nad-plus